Paradigm Peptides: The Gray Market’s Flagship Conviction

Case: U.S. v. Matthew Kawa (Paradigm Peptides) — sentenced July 2026. Court record.

If one case explains why regulators treat the “research use only” peptide market as a fraud problem and not a paperwork problem, it is this one.

What the Court Record Shows

Matthew Kawa, owner of Paradigm Peptides, built one of the gray market’s larger storefronts — roughly 54,000 customers, according to the case record. Three findings from the prosecution define the case:

• Forged certificates of analysis. The lab reports Paradigm showed customers to prove purity and identity were forged. In a market where the COA is the only quality document a buyer ever sees, the paperwork itself was fake.
• Steroids in the vials. Products sold as “testosterone-mimic” compounds actually contained steroids — a different, controlled category of drug than anything the customer believed they were buying.
• He was warned — twice. The FDA sent Paradigm warning letters in 2020 and again in 2022. The sales continued anyway.

The Sentence

In July 2026, Kawa was sentenced to 70 months in federal prison and ordered to forfeit $5 million.

Why This Case Matters

Every element of the gray market’s standard pitch failed here at once. The “research chemical” framing did not protect the seller. The certificates of analysis — the document class that testing watchdogs like Finnrick Analytics and The Peptide Watch exist to audit — were fabricated. And the product in the vial was not the product on the label, which is the precise harm behind the question regulators keep asking buyers: what else is in that vial?

Paradigm is the convicted end of the spectrum this tracker covers. The warning-letter waves show how wide the rest of the spectrum is — and how many sellers kept advertising after being told to stop.

Part of the Peptide Gray Market tracker. Sources: U.S. Department of Justice case record; FDA warning letters (2020, 2022). Compiled October 18, 2026.